ArticleCurrent microbiology2025
Antibacterial Synergism of Fluoxetine and Paroxetine with Ceftriaxone, Plasmid DNA Cleavage and Repositioning.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The indiscriminate use of antibiotics continues to promote a decrease in the sensitivity of bacteria to commercialized antibiotics. Current successful approaches, such as repositioning, enhance new uses for approved drugs. The antibacterial activity of fluoxetine (FX) and paroxetine (PX) combined with ceftriaxone (CTX) was evaluated against 5 standard strains and 72 multidrug-resistant clinical isolates collected in the years 2019 and 2021. FX showed minimum inhibitory concentrations (MIC) from 4 to 256 µg/ml and PX from 1 to 256 µg/ml, demonstrating that antidepressants showed better action than antibiotics (MIC from 512 µg/ml to > 4096 µg/ml). CTX had MIC reduced by 32 thousand times in combination with FX/PX. Antidepressants cleaved plasmid DNA by hydrolytic mechanism, demonstrating greater cleavage efficiency at pH 7.4 and temperature of 37 °C, that is, under physiological conditions. This is a demonstrative study of the promising action of FX/PX in combination with CTX in strains registered in 2019 and 2021, confirming it to be a promising alternative in antibacterial treatments.
Indexed as
Identifiers
40715552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.